Welcome to our dedicated page for Inhibikase Therapeutics SEC filings (Ticker: IKT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Inhibikase Therapeutics, Inc. (Nasdaq: IKT) SEC filings page on Stock Titan provides access to the company’s publicly filed regulatory documents, including current reports on Form 8-K and other submissions made through the U.S. Securities and Exchange Commission’s EDGAR system. As a clinical-stage pharmaceutical company developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease, Inhibikase uses these filings to report material corporate events, financing transactions, governance matters, and key developments in its pulmonary arterial hypertension (PAH) program.
Inhibikase’s recent 8-K filings describe, among other items, the entry into an underwriting agreement for a public offering of common stock and pre-funded warrants, the expected net proceeds from that offering, and amendments to outstanding warrants in connection with plans to advance IKT-001 to a global pivotal Phase 3 study in PAH. Other 8-Ks report financial results for specific periods, updates to corporate presentations, and outcomes of the company’s annual meeting of stockholders, including director elections, auditor ratification, and equity incentive plan amendments.
Through this page, users can review how Inhibikase discloses its clinical development strategy for IKT-001, including the planned two-part adaptive Phase 3 IMPROVE-PAH study, as well as its capital-raising activities that support ongoing research and development. Stock Titan enhances these filings with AI-powered summaries that explain the core points of lengthy documents such as current reports, shelf registration statements, and related exhibits. Investors can also monitor information related to equity offerings, warrant terms, and other securities matters that may affect the company’s capital structure.
By consolidating Inhibikase’s SEC filings and applying AI-driven analysis, this page helps readers quickly understand the regulatory and financial context surrounding the company’s PAH-focused clinical programs and broader corporate activities.
Inhibikase Therapeutics (IKT) reported items in its Form 10-Q showing corporate and development activity ahead of a planned Phase 2b study in pulmonary arterial hypertension (PAH). The company expects to initiate a ~150‑patient Phase 2b trial in the second half of 2025 and used non‑human primate safety studies and a bioequivalence trial in healthy volunteers to set dosing.
Financing and equity actions are material: a private placement included issuance of shares and multiple warrant tranches exercisable at $1.37 and $1.49 with exercise and ownership caps, and 19,665,131 pre‑funded warrants were outstanding at June 30, 2025. An at‑the‑market agreement with HCW was terminated effective December 11, 2024; a separate Sales Agreement with Jefferies and a related shelf registration were in place as of June 27, 2025. The company acquired CorHepta, issuing shares including contingent and performance‑based shares and recognized a $7,357,294 R&D write‑off related to IPR&D.
This Schedule 13G is filed jointly by Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Alternatives, LLC and Frank M. Sands and reports a significant passive position in Inhibikase Therapeutics common stock. The Reporting Persons beneficially own 10,950,000 shares, representing 14.7% of the outstanding class based on 74,341,540 shares outstanding as of May 1, 2025. The position is reported with shared voting and dispositive power of 10,950,000 shares and no sole voting or dispositive power.
The filing expressly excludes a Series A-1 warrant to purchase 5,475,000 shares and a Series B-1 warrant to purchase 10,068,120 shares because neither warrant is exercisable within 60 days; each warrant contains a restriction preventing beneficial ownership in excess of 19.99% immediately after exercise. The Reporting Persons certify the securities are not held to change or influence control of the issuer.
Form 4/A overview: Inhibikase Therapeutics (IKT) filed an amended Form 4 for President & Head of R&D Christopher Cabell. The filing corrects the exercise price to $2.97 on a previously reported stock-option grant covering 1,100,705 common shares originally awarded on Feb 21 2025 and expiring on Feb 21 2035. No other terms change: the options vest in three substantially equal tranches on the 2nd, 3rd and 4th anniversaries of the grant date, contingent on continued service. The amendment does not involve any share sales or purchases and therefore has no immediate cash impact on the company. It simply aligns the public record with the correct contractual terms, maintaining disclosure accuracy and avoiding potential misinterpretation of executive compensation.
FAQ
What is the current stock price of Inhibikase Therapeutics (IKT)?
What is the market cap of Inhibikase Therapeutics (IKT)?
